Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Breast Cancer AND Still's Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7379   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    100 result(s) found for: Breast Cancer AND Still's Disease. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2006-004144-23 Sponsor Protocol Number: 26866138-BCA-2001 Start Date*: 2007-02-12
    Sponsor Name:AZ St Augustinus, Wilrijk
    Full Title: Clinical Trial Application for a Phase II study in patients with hormone receptor positive breast cancer with bortezomib (Velcade) in the reversal of endocrine resistance.
    Medical condition: breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001853-28 Sponsor Protocol Number: I3Y-MC-JPCP Start Date*: 2018-10-31
    Sponsor Name:Lilly S.A.
    Full Title: An Open-Label, Randomized Phase 2 Study of the Impact of Food on Tolerability when Receiving Abemaciclib for Patients with Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Br...
    Medical condition: Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003216-39 Sponsor Protocol Number: IEO674 Start Date*: 2018-12-20
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: Clinical utility of a next generation sequencing-based “oncochip” for therapeutic decision in metastatic breast cancer. Study SHARP
    Medical condition: Metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006285 Breast neoplasm NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-015628-27 Sponsor Protocol Number: CAUY922A2109 Start Date*: 2010-08-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase Ib/II, multi-center, open-label study to evaluate the efficacy of AUY922 in combination with Trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer, that ha...
    Medical condition: locally advanced or metastatic HER2-positive breast cancer, that has progressed after or during at least one Trastuzumab-containing regimen
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed) FR (Completed) GB (Completed) DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-002514-12 Sponsor Protocol Number: FACILE Start Date*: 2019-11-12
    Sponsor Name:FONDAZIONE SANDRO PITIGLIANI PER LA LOTTA CONTRO I TUMORI - ONLUS
    Full Title: Phase II, multicenter, single arm trial to assess the feasibility of first line ribociclib in combination with a non steroidal aromatase inhibitor in elderly patients with hormone receptor positive...
    Medical condition: HR+, HER2 negative advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-000898-68 Sponsor Protocol Number: 2013/VCC/0008 Start Date*: 2014-01-24
    Sponsor Name:Velindre NHS Trust
    Full Title: A phase 1b/2 randomised placebo controlled trial of fulvestrant +/- AZD5363 in postmenopausal women with advanced breast cancer previously treated with a third generation aromatase inhibitor.
    Medical condition: Estrogen receptor positive advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-022902-41 Sponsor Protocol Number: BIG4-11/BO25126/TOC4939g Start Date*: 2011-09-26
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in pa...
    Medical condition: Patients with operable HER2-positive primary breast cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) CZ (Completed) ES (Ongoing) FR (Completed) IE (Completed) SE (Completed) DK (Completed) SI (Completed) NL (Completed) BE (Completed) SK (Completed) AT (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-003283-20 Sponsor Protocol Number: MO21926 Start Date*: 2009-02-09
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Estudio de fase II abierto, con un solo grupo de tratamiento, de bevacizumab en combinación con trastuzumab y capecitabina como tratamiento en primera línea de pacientes con cáncer de mama localmen...
    Medical condition: Tratamiento de pacientes con cáncer de mama localmente recurrente o metastásico HER2- positivo que no han recibido previamente quimioterapia para enfermedad localmente recurrente o metastásica. H...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027475 Metastatic breast cancer LLT
    9.1 10065430 HER-2 positive breast cancer LLT
    9.1 10006198 Breast cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Ongoing) SE (Completed) SK (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-001652-36 Sponsor Protocol Number: UC-0105/1304 Start Date*: 2014-01-17
    Sponsor Name:UNICANCER
    Full Title: Evaluation of the efficacy of high throughput genome analysis as a therapeutic decision tool for patients with metastatic breast cancer
    Medical condition: Patients with metastatic breast cancer in 1st or 2nd line of chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-005335-97 Sponsor Protocol Number: GO25632 Start Date*: 2012-10-11
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of bevacizumab, and associated biomarkers, in combination with paclitaxel compared w...
    Medical condition: HER2-negative metastatic breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000579-12 Sponsor Protocol Number: D4200L00009 Start Date*: 2008-12-03
    Sponsor Name:ASTRAZENECA
    Full Title: A randomised, double-blind, parallel-group, multicentre, phase ii study to evaluate the safety and pharmacological activity of the combination of Vandetanib (100 or 300 mg/daily or placebo) with Fu...
    Medical condition: Postmenopausal women with advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004234-15 Sponsor Protocol Number: CLEE011A2207 Start Date*: 2019-05-24
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- an...
    Medical condition: HR-positive, HER2-negative advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    23.0 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    21.1 100000004864 10072737 Advanced breast cancer LLT
    20.0 100000004864 10073289 Premenopausal breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) SE (Completed) CZ (Completed) FR (Completed) LT (Completed) AT (Completed) FI (Completed) DE (Completed) PT (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2004-002371-16 Sponsor Protocol Number: D6997C00002 (9238IL/0064) Start Date*: 2004-11-18
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-Blind, Parallel-group, Multicentre, Phase III Study Comparing the Efficacy and Tolerability of Fulvestrant (FASLODEX™) 500 mg with Fulvestrant (FASLODEX™) 250 mg in Postmenopau...
    Medical condition: Postmenopausal women with advanced breast cancer, progressing or relapsing after previous endocrine therapy
    Disease:
    Population Age: Elderly Gender: Female
    Trial protocol: SK (Completed) CZ (Completed) HU (Completed) ES (Completed) IT (Completed) MT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000348-28 Sponsor Protocol Number: BO15943 Start Date*: 2007-08-30
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A single arm, multi-centre, international, continuation trial of recombinant humanized antibody Herceptin® (trastuzumab) in patients with HER2 overexpressing tumors.
    Medical condition: To continue to provide treatment to those patients that may still be on treatment at the moment of the final data base closure/clinical cut-off of a clinical trials in which Herceptin® is investiga...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-004139-62 Sponsor Protocol Number: CRAD001JES13 Start Date*: 2014-01-02
    Sponsor Name:Novartis Farmacéutica S. A.
    Full Title: A pilot open-label, phase II, single-arm study to evaluate the association of biomarkers of hormonal resistance and the mTOR pathway with the clinical efficacy of everolimus plus letrozole in the f...
    Medical condition: Estrogen receptor or progesterone receptor positive locally advanced or metastatic breast cancer in postmenopausal women
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020998-16 Sponsor Protocol Number: MO22998 Start Date*: 2010-11-22
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: ESTUDIO FASE III RANDOMIZADO PARA EVALUAR LA EFICACIA Y SEGURIDAD DEL TRATAMIENTO CONTINUADO Y DE REINDUCCIÓN CON BEVACIZUMAB EN COMBINACIÓN CON QUIMIOTERAPIA EN PACIENTES CON CÁNCER DE MAMA LOCALM...
    Medical condition: Locally recurrent (LR) or metastatic breast cancer (mBC) progressing after first-line chemotherapy and bevacizumab treatment. Pacientes con cáncer de mama localmente recurrente (LR) o metastásico (...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10055113 Breast cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) SK (Completed) HU (Completed) AT (Completed) DE (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003159-73 Sponsor Protocol Number: MM-302-02-02-03 Start Date*: 2015-05-29
    Sponsor Name:Merrimack Pharmaceuticals, Inc.
    Full Title: HERMIONE: A Randomized, Multicenter, Open Label Study of MM-302 plus Trastuzumab vs. Chemotherapy of Physician’s Choice plus Trastuzumab in Anthracycline Naive Patients with Locally Advanced/Metast...
    Medical condition: Locally Advanced/Metastatic HER2-Positive Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) IT (Completed) BE (Prematurely Ended) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004734-22 Sponsor Protocol Number: WO39392 Start Date*: 2017-09-06
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE III RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH NEOADJUVANT ANTHRACYCLINE/NAB-PACLITAXEL-BASED CHEMOTHERAPY COMPARED WI...
    Medical condition: Triple-negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039850 Secondary malignant neoplasm of breast LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) PL (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000198-29 Sponsor Protocol Number: CD-ON-MEDI-573-1030 Start Date*: 2011-10-25
    Sponsor Name:MedImmune, LLC
    Full Title: A Phase 1b/2 Randomized Study of MEDI-573 in Combination with an Aromatase Inhibitor (AI) Versus AI Alone in Women with Metastatic Breast Cancer (MBC)
    Medical condition: Advanced Metastatic Breast Cancer (MBC)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006202 Breast cancer stage IV PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) DE (Completed) HU (Completed) BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-002766-20 Sponsor Protocol Number: CAUY922A2101 Start Date*: 2009-02-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase I dose escalation, multi-center, open-label study of AUY922 administered IV on a once-weekly schedule in adult patients with advanced solid malignancies including phase II expansion arms in...
    Medical condition: Dose-expansion study to assess safety, tolerability & efficacy: -One arm (MTD expansion) will enroll advanced cancer patients (other than breast carcinoma). -Two arms (phase II) to assess response ...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) DE (Prematurely Ended) NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Aug 06 08:43:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA